Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Remarkably Stable Virus-Like Positive Controls for COVID-19 Assays

By LabMedica International staff writers
Posted on 09 Dec 2020
Researchers have prepared a new class of positive control materials to validate the molecular assays that have been developed to detect and diagnose COVID-19 infection.

Nucleic acid tests, especially reverse transcription polymerase chain reaction (RT-PCR), have become the standards for early detection of COVID-19 infection. More...
Positive controls for the molecular assays have been developed to validate each test and to provide high accuracy. However, most available positive controls require cold-chain distribution and cannot serve as full-process controls.

To overcome these shortcomings, investigators at the University of California, San Diego (USA) have developed new and improved positive controls. The investigators developed two different controls: one made from plant virus nanoparticles, the other from bacteriophage nanoparticles.

The plant virus-based controls were made using cowpea chlorotic mottle virus. The investigators removed the RNA contents of the virus and replaced them with a synthesized RNA template containing specific sequences from the SARS-CoV-2 virus.

Plasmids (segments of circular DNA) were used to make the bacteriophage-based controls. Plasmids containing gene sequences from the SARS-CoV-2 virus, as well as genes coding for surface proteins of the bacteriophage Qbeta, were loaded into bacteria. The bacteria then generated virus-like particles with SARS-CoV-2 RNA sequences on the inside and Qbeta bacteriophage proteins on the outside.

Results revealed that the positive control materials were detected accurately in COVID-19 molecular assays. The controls were stable and could be stored for a week at temperatures up to 40 degrees Celsius while retaining 70% of their activity after one month of storage.

"Our goal is to make an impact not necessarily in the hospital, where you have state-of-the-art facilities, but in low-resource, under served areas that may not have the sophisticated infrastructure or trained personnel," said senior author Dr. Nicole Steinmetz, professor of nanoengineering at the University of California, San Diego. "It is a relatively simple nanotechnology approach to make low-tech assays more accurate. "This could help break down some of the barriers to mass testing of under served populations in the United States and across the world."

The new COVID-19 positive controls were described in the November 25, 2020, online edition of the journal ACS Nano.

Related Links:
University of California San Diego


Platinum Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Sample Transport
VACUETTE Transport Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.